CN111543635A - Health food with weight reducing function and preparation method thereof - Google Patents
Health food with weight reducing function and preparation method thereof Download PDFInfo
- Publication number
- CN111543635A CN111543635A CN202010479158.7A CN202010479158A CN111543635A CN 111543635 A CN111543635 A CN 111543635A CN 202010479158 A CN202010479158 A CN 202010479158A CN 111543635 A CN111543635 A CN 111543635A
- Authority
- CN
- China
- Prior art keywords
- weight
- parts
- health food
- losing
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013402 health food Nutrition 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 230000000694 effects Effects 0.000 claims abstract description 22
- 239000000463 material Substances 0.000 claims abstract description 22
- 239000002994 raw material Substances 0.000 claims abstract description 22
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 21
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 21
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 21
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 17
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 17
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 16
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 16
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims abstract description 15
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 12
- 208000008589 Obesity Diseases 0.000 claims abstract description 10
- 235000020824 obesity Nutrition 0.000 claims abstract description 10
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 6
- 244000269722 Thea sinensis Species 0.000 claims abstract 5
- 239000002775 capsule Substances 0.000 claims description 47
- 235000013305 food Nutrition 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 238000001694 spray drying Methods 0.000 claims description 11
- 238000005303 weighing Methods 0.000 claims description 11
- 238000001914 filtration Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 238000004806 packaging method and process Methods 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 8
- 238000005498 polishing Methods 0.000 claims description 8
- 238000007873 sieving Methods 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 7
- 210000000582 semen Anatomy 0.000 claims description 7
- 239000006187 pill Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 9
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 229940100691 oral capsule Drugs 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 239000003925 fat Substances 0.000 description 28
- 235000019197 fats Nutrition 0.000 description 28
- 238000012360 testing method Methods 0.000 description 27
- 241000700159 Rattus Species 0.000 description 20
- 230000008859 change Effects 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 210000000577 adipose tissue Anatomy 0.000 description 12
- 235000005911 diet Nutrition 0.000 description 12
- 241001122767 Theaceae Species 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 230000037213 diet Effects 0.000 description 10
- 210000004003 subcutaneous fat Anatomy 0.000 description 10
- 230000037396 body weight Effects 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 210000002700 urine Anatomy 0.000 description 9
- 238000011049 filling Methods 0.000 description 8
- 235000015097 nutrients Nutrition 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 230000002354 daily effect Effects 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 230000004580 weight loss Effects 0.000 description 5
- 206010010774 Constipation Diseases 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 230000036528 appetite Effects 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000005686 eating Nutrition 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000036284 oxygen consumption Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000037080 exercise endurance Effects 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000007958 sleep Effects 0.000 description 3
- 210000001113 umbilicus Anatomy 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000002594 fluoroscopy Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 244000025596 Cassia laevigata Species 0.000 description 1
- 235000006693 Cassia laevigata Nutrition 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- YXVXMURDCBMPRH-UHFFFAOYSA-N Lirinidine Natural products C1C2=CC=CC=C2C2=C(O)C(OC)=CC3=C2C1N(C)CC3 YXVXMURDCBMPRH-UHFFFAOYSA-N 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- ORJVQPIHKOARKV-UHFFFAOYSA-N Nuciferine Natural products C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2C1N(C)CC3 ORJVQPIHKOARKV-UHFFFAOYSA-N 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000009557 abdominal ultrasonography Methods 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000011976 chest X-ray Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000000028 corpus adiposum pararenale Anatomy 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000000852 deltoid muscle Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000008242 dietary patterns Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000000527 greater trochanter Anatomy 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 210000003692 ilium Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 239000010699 lard oil Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 229960003283 lorcaserin hydrochloride Drugs 0.000 description 1
- ITIHHRMYZPNGRC-QRPNPIFTSA-N lorcaserin hydrochloride Chemical compound Cl.C[C@H]1CNCCC2=CC=C(Cl)C=C12 ITIHHRMYZPNGRC-QRPNPIFTSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- ORJVQPIHKOARKV-OAHLLOKOSA-N nuciferine Chemical compound C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2[C@@H]1N(C)CC3 ORJVQPIHKOARKV-OAHLLOKOSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 210000001991 scapula Anatomy 0.000 description 1
- 229940124513 senna glycoside Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the field of traditional Chinese medicine health food preparations, and particularly relates to a health food with a weight-losing function and a preparation method thereof. The weight-losing health food comprises the following raw materials in parts by weight: 5-15 parts of cassia seed extract, 5-15 parts of lotus leaf extract, 2-10 parts of tea polyphenol and 15-30 parts of L-carnitine. The weight-losing health food provided by the invention is prepared into an oral capsule dosage form by taking natural raw materials as main components and magnesium stearate as a forming agent as an auxiliary material, is purely natural in materials, does not add any chemical synthesis reagent medicines, has no toxic or side effect, and is safe to use; the weight-losing tea is unique in formula and reasonable in proportion, has an obvious weight-losing effect, does not rebound, and is suitable for people with simple obesity.
Description
Technical Field
The invention belongs to the field of traditional Chinese medicine health product preparations, and particularly relates to a health food with a weight-losing function and a preparation method thereof.
Background
With the increasing improvement of living standard of people, obesity becomes a social phenomenon, which is metabolic syndrome, the disease process is complex, the harm is serious, the obesity can cause arteriosclerosis of human body, damage important organs of human body such as heart, brain, liver, kidney and the like, and can simultaneously cause serious consequences such as hypertension, diabetes, renal insufficiency, cerebral apoplexy and the like. Modern studies have shown that obesity is a disease caused by disturbances in appetite and energy regulation, and is associated with a variety of factors including genetics, environment, dietary pattern, and the like.
Obesity is divided into a plurality of minutes, wherein the principle of simple obesity is that the body takes excessive calorie, namely, the calorie is taken more than the calorie consumed by the body, and the excessive calorie is converted into fat for storage. Energy required by human bodies in the process of life activities mainly comes from food, and nutrients contained in animal and plant food can be divided into six types: carbohydrates, fats, proteins, minerals, vitamins and dietary fibres, plus water, fall into seven broad categories. Among them, carbohydrates, fats and proteins are oxidized in vivo to release energy, and the three are collectively called "energy-producing nutrients" or "pyrogens", and these three types of nutrients are commonly found in various foods.
At present, the types of weight-losing products sold in the market are three, and more defects and shortcomings exist: 1. a Chinese medicine in the form of weight-losing food for treating constipation due to heat accumulation, abdominal distention, etc is prepared from rhubarb, senna leaf and aloe through immersing them in it, and features quick action, no need of losing weight. 2. Enzyme products: the ferment is an enzyme, and the ferment product is helpful for gastrointestinal digestion of people, and even if the ferment product has a certain effect of relaxing bowel, the ferment product also has the effect of oligosaccharide, lactobacillus and the like added in the product. The ferment can promote the decomposition of fat, but the fat cannot be burnt, and the faster the fat is decomposed, the better the intestinal absorption can be theoretically realized, so that the effect of losing weight is difficult to play. Indeed, the actual useful weight loss drugs act by a mechanism that is contrary to the mechanism declared in the enzymatic weight loss promotion, not by increasing the enzyme intake, but rather by inhibiting lipase, to control fat absorption. Essentially all of the conventional enzymes have no direct weight loss effect, and some enzymes can help digestion well and even increase body weight reliably. 3. Chemical medicine type weight-reducing products, such as sibutramine, orlistat, lorcaserin hydrochloride and prescription weight-reducing medicines, have serious adverse reactions such as allergy, serious liver and kidney damage, pancreatitis and the like in adverse event monitoring after the products are on the market.
Therefore, most of the products with the weight-losing and health-care functions on the market are cold and cool in properties, and the metabolism of the human body is accelerated, so that the weight-losing effect is achieved; or chemical compound product is used for inhibiting appetite of human body and violently controlling diet, thereby achieving the effect of losing weight; the weight-losing method has great influence on human bodies and even has certain potential safety hazard.
Disclosure of Invention
On the basis of overcoming the defects of the prior art, the invention provides a health food prepared by taking cassia seed extract, lotus leaf extract, tea polyphenol and L-carnitine as raw materials and a preparation method thereof, wherein the raw materials belong to homology of medicine and food, and the raw materials have mild properties and do not contain energy nutrients. The weight-losing health food has the characteristics of high safety factor, good weight-losing effect, no toxic or side effect and the like, and is deeply favored by the masses of weight-losing people because the weight does not rebound after the weight is reduced by changing the body metabolism mode.
The invention is realized by the following technical scheme:
on one hand, the health food with the weight-losing function is provided, and is characterized by comprising the following raw materials in parts by weight: 3-15 parts of cassia seed extract, 3-15 parts of lotus leaf extract, 2-10 parts of tea polyphenol and 15-30 parts of L-carnitine.
Further, the feed comprises the following raw materials in parts by weight: 4-10 parts of cassia seed extract, 4-10 parts of lotus leaf extract, 2-8 parts of tea polyphenol and 15-25 parts of L-carnitine.
Further, the preparation method of the cassia seed extract comprises the following steps: weighing semen cassiae, crushing, performing reflux extraction for 2-3 times by adopting 50-75% edible alcohol, adding 4-6 times of edible alcohol by weight each time, extracting for 1-2 hours each time, and then filtering, concentrating, spray drying and packaging to obtain semen cassiae extract;
further, the preparation method of the lotus leaf extract comprises the following steps: weighing lotus leaves, crushing, adding 6-10 times of water by weight, performing reflux extraction for 3-4 times for 1-2 h each time, and then filtering, concentrating, spray drying and packaging to obtain a lotus leaf extract;
furthermore, the water content of the cassia seed extract and the lotus leaf extract is less than or equal to 5 percent.
Furthermore, the inlet temperature of the spray drying is 180-200 ℃, and the outlet temperature is 80-90 ℃.
The invention uses the following medicinal materials:
cassia seed: has effects of loosening bowel to relieve constipation, and promoting decomposed fat to be discharged from body, and is especially suitable for patients with excessive obesity and constipation.
Lotus leaf: clearing away summer heat, eliminating dampness, promoting hair growth, and clearing yang. Can be used for treating diarrhea due to summer-heat and dampness, and diarrhea due to spleen deficiency. The nuciferine is extracted, so that fat is effectively decomposed and is forcefully discharged out of the body; the intestinal wall of the human body is densely covered to form an isolation film to prevent fat absorption and fat accumulation; change the greasy eating habit.
Tea polyphenol: is a general term of polyphenol substances in tea, and tea polyphenol can be directly combined with fatty acid to promote lipid to be discharged out of a body; the tea polyphenols can inhibit body absorption of fat, change energy metabolism disorder, and prevent energy accumulation and conversion into fat; consuming excess body fat, converting it into energy required daily.
L-carnitine: the L-carnitine is a similar amino acid for promoting fat to be converted into energy, the metabolic process of the fat passes through a barrier-mitochondrial membrane, and the L-carnitine plays a role of carrying, so that long-chain fatty acid is carried into mitochondria to be further oxidized and decomposed.
In another aspect, a method for preparing a health food with a weight-reducing function is provided, which comprises the following steps:
s1, weighing the cassia seed extract, the lotus leaf extract, the tea polyphenol and the L-carnitine according to the formula, sieving by a 40-60-mesh sieve, and placing in a mixer;
s2, weighing the auxiliary materials according to the formula, sieving the auxiliary materials by a 40-60-mesh sieve, placing the auxiliary materials in a mixer, and mixing the auxiliary materials with the raw materials obtained in the step S1 for 20-40 min to prepare a total mixed material;
s3, encapsulating, polishing and packaging the total mixed material obtained in the step S2 to obtain capsules.
Furthermore, the auxiliary material in the step S2 is magnesium stearate, and the added parts are 0.3-0.9 parts.
Further, after step S1, the composition can be made into tablet or pill.
In another aspect, the health food is suitable for weight loss of simply obese people.
Has the advantages that:
1. the invention adopts L-carnitine, cassia seed extract, lotus leaf extract and tea polyphenol as main raw materials, and the selected traditional Chinese medicinal materials belong to homology of medicine and food, have mild properties, can not cause any damage to human bodies, and do not influence normal appetite.
2. The weight-losing mechanism of the invention follows the weight-losing principle proposed by the world health organization, and the invention does not need to be dieted, does not influence normal appetite, does not need a large amount of strenuous exercise and does not need diarrhea. The health food prepared by the invention does not contain energy nutrients, is suitable for people who are simply obese, performs animal experiments and human body experiments on the efficacy and safety of the product, and has the characteristics of high safety coefficient, good weight-losing effect, high product quality, high bioavailability, good stability, mild taste, no pungent smell, no toxic or side effect and the like.
3. The raw materials are strictly and finely screened, alcohol extraction or water extraction is carried out according to different properties of the traditional Chinese medicinal materials, effective ingredients are accurately extracted, and the traditional Chinese medicine composition is prepared by a series of procedures of crushing, sieving, granulating, filling, checking the filling amount, encapsulating in capsules and encapsulating outside the capsules. The preparation method is simple and quick.
Detailed Description
The present invention is further described in the following examples, which should not be construed as limiting the scope of the invention, but rather as providing the following examples which are set forth to illustrate and not limit the scope of the invention.
Example 1
A health food with weight-losing function and a preparation method thereof are composed of the following raw materials in parts by weight:
calculated by 1000 capsules (specification: 0.40 g/capsule)
Health food with weight reducing function and preparation method thereof
1) Preparation of the extract:
and (2) cassia seed extract: through crushing, extracting with 5 times of 50% ethanol under reflux for 3 times, each time for 1 hr, filtering, concentrating, spray drying at inlet temperature of 180-.
Lotus leaf extract: through the main processes of crushing, extracting (5 times of water is extracted for 4 times at 100 ℃ for 1 hour each time), filtering, concentrating, spray drying (the inlet temperature is 180-.
2) Preparing the weight-losing health-care food capsule:
s1, pretreatment: sieving semen Cassiae extract, folium Nelumbinis extract, tea polyphenols, L-carnitine, and magnesium stearate with 40 mesh sieve.
S2, mixing: weighing the sieved raw materials according to the formula proportion, and putting the raw materials into a mixer for total mixing.
S3, capsule filling: the mixed material was filled on an automatic capsule filling machine with 0.40g of the contents per capsule. The operation condition requires that the temperature is 18-25 ℃ and the relative humidity is below 65%.
S4, polishing capsules: polishing the filled capsules on a capsule polishing machine to obtain the weight-losing health-care food capsules.
Example 2
A health food with weight-losing function and a preparation method thereof are composed of the following raw materials in parts by weight:
calculated by 1000 capsules (specification: 0.40 g/capsule)
Health food with weight reducing function and preparation method thereof
1) Preparation of the extract:
and (2) cassia seed extract: through crushing, extracting with 4 times 60% ethanol under reflux for 3 times (1 hr each time), filtering, concentrating, spray drying at 180 deg.C and 70 deg.C, and packaging.
Lotus leaf extract: through the main processes of crushing, extracting (4 times of water extraction for 3 times at 100 ℃ and 1 hour each time), filtering, concentrating, spray drying (inlet temperature is 180 ℃ and outlet temperature is 70 ℃), packaging and the like.
2) Preparing the weight-losing health-care food capsule:
s1, pretreatment: sieving semen Cassiae extract, folium Nelumbinis extract, tea polyphenols, L-carnitine, and magnesium stearate with 40 mesh sieve.
S2, mixing: weighing the sieved raw materials according to the formula proportion, and putting the raw materials into a mixer for total mixing.
S3, capsule filling: the mixed material was filled on an automatic capsule filling machine with 0.40g of the contents per capsule. The operation condition requires that the temperature is 18-25 ℃ and the relative humidity is below 65%.
S4, polishing capsules: polishing the filled capsules on a capsule polishing machine to obtain the weight-losing health-care food capsules.
Example 3
A health food with weight-losing function and a preparation method thereof are composed of the following raw materials in parts by weight:
calculated by 1000 capsules (specification: 0.40 g/capsule)
Health food with weight reducing function and preparation method thereof
1) Preparation of the extract:
and (2) cassia seed extract: through the main processes of crushing, extraction (6 times of 50% ethanol content, reflux extraction for 3 times, 1 hour each time), filtration, concentration, spray drying (inlet temperature 180-.
Lotus leaf extract: through the main processes of crushing, extracting (6 times of water is extracted for 4 times at 100 ℃ for 1 hour each time), filtering, concentrating, spray drying (inlet temperature is 200 ℃ and outlet temperature is 90 ℃), packaging and the like.
2) Preparing the weight-losing health-care food capsule:
s1, pretreatment: sieving semen Cassiae extract, folium Nelumbinis extract, tea polyphenols, L-carnitine, and magnesium stearate with 40 mesh sieve.
S2, mixing: weighing the sieved raw materials according to the formula proportion, and putting the raw materials into a mixer for total mixing.
S3, capsule filling: the mixed material was filled on an automatic capsule filling machine with 0.40g of the contents per capsule. The operation condition requires that the temperature is 18-25 ℃ and the relative humidity is below 65%.
Example 4
(I) animal experiments
1. The material and the method are as follows:
1.1 sample: the weight-losing health food capsule prepared in example 1.
1.2 Experimental animals: purchased from laboratory animal center of military medical science institute of the people's liberation force, clean-grade Wistar rat, male, body weight 126-. The approved letter number is SCXK- (military) -2002-. Barrier environment, the license number for experimental animals was SYXK (lu) 20030006.
1.3 adopting obesity prevention model method, setting blank control group, model control group and 3 tested sample groups. The human recommended amount of test sample is 1.6g/60kg body weight per day, with the dose set as: the 0.13g/kg body weight group, 0.27g/kg body weight group, and 0.81g/kg body weight group were 5 times, 10 times, and 30 times the recommended intake amount of human body, respectively. The samples were adjusted to the required concentration with distilled water, and the gavage was performed orally at a rate of 1.0ml/100g body weight per day, and the same volume of distilled water was used for gavage in the blank control group and the model control group. After the continuous oral gavage for 42 days, various indexes were measured.
1.4 Instrument and reagents: animal balance, dissecting instrument.
1.5 Experimental methods: method for preventing obesity model
1.5.1 nutrient feed formula: 80% of basic feed, 10% of lard oil and 10% of egg yolk powder.
1.5.2 Experimental procedures: animals are randomly divided into a blank control group, a model control group and three test sample groups, from the beginning of an experiment, each animal of the model control group and the test sample group is fed with equal amount of nutrient feed every day, the blank control group is fed with basic feed, and the feed feeding amount is the same as that of the nutrient feed. The test sample group was administered with different doses of test samples by gavage, and the blank control group and the model control group were administered with respective volumes of distilled water. The feed, food remaining and feed broadcast were recorded for each animal during the experiment, weighed 2 times per week, weighed at the end of the experiment, and body fat (testicular and perirenal fat pads) was extracted via laparotomy and weighed, and the fat/body ratio was calculated.
1.6 Experimental data A database was created using Exce1, and data analysis of variance was performed using SPSS software, followed by statistical analysis using pairwise comparison of mean values between experimental and control groups (Dunnett test).
2. Results
2.1 Effect of diet health food Capsule on rat weight
TABLE 1 weight effect of weight loss health food capsules on rat body weight (g)
Note: 1) representation to blank control group, 2) representation to model control group
As can be seen from Table 1, after the weight-reducing health food capsule is orally administered to rats for 42 days, the weight of rats in the model control group is obviously increased, and the weight of the rats has significant difference (p is less than 0.01) compared with that of the rats in the blank control group; the weight and weight gain of rats in the low and medium dose groups are obviously lower than those of the model control group, and the difference is significant (p is less than 0.05).
2.2 Effect of weight-reducing health food Capsule on food intake and in vivo fat of rats
TABLE 2 Effect of fat-reducing health food Capsule on rat body fat
TABLE 2
Note: 1) representation to blank control group, 2) representation to model control group
As can be seen from Table 2, after the weight-reducing health food capsule is orally administered to rats for 42 days, the increase of the fat weight in rats in the model control group is obvious, and the fat weight in rats in the low and medium dose groups is significantly different (p is less than 0.01) compared with that in the blank control group, and the fat weight in rats in the low and medium dose groups is significantly different (0 is less than 0.05) compared with that in the model control group; compared with the model control group, the total food intake of the rats in the low, medium and high dose groups has no significant difference, the food utilization rate of the rats in the medium and high dose groups is obviously lower than that of the rats in the model control group, and the difference has significance (p is less than 0.01).
4. Conclusion
The experimental result shows that after the weight-losing health-care food capsule is orally administered to rats for 2 days, the total food intake of the rats in each group has no obvious difference, and the low and medium dose groups can obviously control the weight increase of the rats and can obviously reduce the in-vivo fat weight of the rats. The weight-losing health-care food capsule is prompted to have a certain weight-losing effect.
(II) clinical trials
1 objects and methods:
1.1 test substance: the weight-losing health food capsule prepared in example 1 has a content of brown yellow powder. The recommended dose for human body is 2 times daily, 2 granules each time, and the dose is 1.6 g/day.
1.2 subjects:
1.2.1 Inclusion criteria: the BMI of the simple obese people is more than or equal to 30, or the total fat percentage reaches more than 25 percent for men and more than 30 percent for women.
1.2.2 exclusitor criteria:
1) it is also suitable for patients with severe diseases of heart, cerebral vessels, liver, kidney, and digestive tract.
2) Pregnant or lactating women, allergic constitution or those allergic to the test sample.
3) Taking articles related to the tested function in a short time affects the result judgers.
4) If the tested sample is not taken according to the standard, the efficacy or safety judgment is not affected by the incomplete data.
1.3 Experimental design and grouping: the two forms of self-front-back control and group-between control are adopted. The subjects were randomly divided into an experimental group and a control group, the experimental group was administered with the test substance, and the control group was a blank control.
1.4 dose and time: 2 capsules each time, 2 times daily, 1.6 g/day for 35 consecutive days.
1.5 Instrument and reagents: CA-500 model blood cell counter (Japan), RM-200 urine analyzer (American national product), AUTOLAB full-automatic biochemical analyzer (Italy), TANITA body fat analyzer (Japan), MONARK-828E power bicycle (Sweden), and biochemical kit are all provided by Zhongsheng corporation.
2, observation indexes are as follows:
the following observation indexes were examined once before and after the experiment.
2.1 safety observations:
2.1.1 general conditions: including mental, sleep, diet, stool and urine, blood pressure, etc.
2.1.2 routine examination of blood, urine and feces: red blood cell count, hemoglobin, white blood cell count, urine routine, stool routine.
2.1.3 Biochemical examination of blood: serum albumin, total protein, glutamic-oxalacetic transaminase, glutamic-pyruvic transaminase, total bilirubin, urea nitrogen, inosine, uric acid, blood sugar, total cholesterol, triglyceride and high-density lipoprotein cholesterol.
2.1.4 Abdominal ultrasonography B, Electrocardiogram, X-ray chest fluoroscopy (performed before the start of the experiment)
2.1.5 diet factors and exercise observations: the subject is subjected to inquiry method diet survey for three days before the start and the end of the experiment to eliminate the influence of diet factors on the experiment result. It is required to be as consistent as possible with the daily diet. During the experiment, the exercise condition of the subject is inquired and observed, and the exercise condition is required to be consistent with the daily exercise condition.
2.1.6 exercise endurance test: the subjects used a power cycle to measure exercise endurance (power 50 watts, time 5 minutes) before and after weight loss. The maximum oxygen consumption of the subject is inferred by recording the exercise heart rate using a telemetric heart rate recorder.
2.1.7 adverse reaction observations: anorexia, diarrhea, etc.
2.2 Observation of efficacy:
2.2.1 weight and height: when the front evacuation and the defecation are measured, the shoes are taken off, and the front and the back weight of the patient are measured, the same clothes are worn on the same weight scale for measurement.
2.2.2 analysis of human body composition: the body fat rate and body fat weight of the human body are measured.
2.2.3 measurement of waist and hip circumference:
waist circumference: the abdominal circumference of the flat umbilicus; hip circumference: the circumference horizontal to the greater trochanter of the femur on both sides.
2.2.4 sebum thickness determination:
the middle point of the abdomen of the triceps brachii muscle, the lower corner of the right shoulder blade, 3cm beside the right umbilicus, and the anterior superior spine of the right ilium.
2.2.5 symptom Observation:
the integral method is adopted, subjective symptoms such as diet, sleep, defecation, tiredness and hypodynamia, hyperhidrosis, constipation and the like are used as indexes, an integral value is counted before and after eating according to the severity of each symptom (3 minutes for severe symptoms, 2 minutes for moderate symptoms and 1 minute for mild symptoms) in a questionnaire form, and the improvement rate is calculated according to the improvement of the main symptoms (2 minutes for significant effect for improvement of each symptom and 1 minute for effective improvement of each symptom).
3, data processing and result judgment:
3.1 data processing: the analytical data were calculated with the statistical software STATE 6.0. The self-contrast data adopts paired t test, the comparison of two groups of means adopts grouped t test, the latter needs to carry out variance homogeneity test, carries out proper variable conversion on data with non-normal distribution or uneven variance, and carries out t test on the converted data after satisfying normal variance homogeneity; if the converted data still can not satisfy the normal varianceChanging t' test or rank sum test for homogeneity requirement; but data with too large coefficient of variation (CV > 50%) were tested using rank sum. X for efficacy index2And (6) checking.
3.2 efficacy determination criteria:
the method has the following advantages: compared with the trial group and the control group after trial, the weight of fat in the body is reduced, at least two points of four points of subcutaneous fat are reduced, one of the waist and hip circumference is reduced, the difference is significant (P is less than 0.05), the exercise endurance is not reduced, the influence of diet and exercise on the weight-losing function is eliminated, and the health of the body is not influenced.
And (4) invalidation: the above standard is not met.
4, results:
4.1 general conditions:
a total of 100 subjects were observed and randomly divided into an experimental group and a control group. The routine of blood, routine of urine, routine of stool, liver and kidney function, chest X-ray, electrocardiogram, B-ultrasonic examination before test of the subject are all in the normal range, the grouping condition is shown in table 1, and the age, sex, weight index and fat percentage of two groups of patients before test feeding have no obvious difference (P is more than 0.05), and have comparability. The testee had no obvious changes in spirit, sleep, diet, stool and urine, blood pressure, etc. before and after the test.
TABLE 1 comparison of general data before eating trials
| Item | Test food group | Control group |
| Number of examples | 50 | 50 |
| Male/female | 13/37 | 13/37 |
| Age (year) | 45.28±5.44 | 45.22±6.02* |
| Course of disease (year) | 11.25±4.19 | 11.58±4.73* |
| Body mass index | 28.26±3.88 | 28.27±2.66* |
| Percentage of fat | 36.43±3.50 | 35.74±3.16* |
Control between groups*P＞0.05
4.2 body weight, body fat mass and percent fat changes:
4.2.1 weight change:
TABLE 2 weight (kg) Change before and after eating trial (X + -SD) after eating trial
Comparison between self and group P > 0.05 before and after the test.
4.2.2 body fat mass and percent fat changes:
TABLE 3 Change in body fat mass (kg) before and after tasting (X + -SD)
Control # P < 0.05 between self-control P < 0.05 groups
TABLE 4 percent (%) fat change before and after tasting (X + -SD)
Self control P < 0.01 group control # P < 0.01
4.3 waist and hip circumference variation
4.3.1 waist circumference variation
TABLE 5 waist circumference (cm) variation before and after tasting (X + -SD)
Self control P < 0.01 control # between groups < 0.01
4.3.2 variation of hip circumference
TABLE 6 waist circumference (cm) variation before and after tasting (X + -SD)
Comparison between self and group P > 0.05 before and after the test.
4.4 subcutaneous fat thickness variation
4.4.1 change in subcutaneous fat thickness at the lateral midpoint of the inferior limbus arm of the right deltoid muscle (Point A)
TABLE 7 Change in subcutaneous fat thickness (cm) at A Point before and after tasting (X + -SD)
Comparison between self and group P > 0.05 before and after the test.
4.4.2 Change in the thickness of the subcutaneous fat in the lower corner of the Right scapula (Point B)
TABLE 8 Change in subcutaneous fat thickness (cm) at B Point before and after tasting (X + -SD)
Comparison between self and group P > 0.05 before and after the test.
4.4.3 Change in subcutaneous fat thickness by 3cm (Point C) near the Right umbilicus
TABLE 9 Change in subcutaneous fat thickness (cm) at C points before and after tasting (X + -SD)
Self control P < 0.05 control # P < 0.01
4.4.4 thickness Change of subcutaneous fat in anterior superior Right iliac spine (Point D)
TABLE 10 Change in subcutaneous fat thickness (cm) at D points before and after tasting (X + -SD)
Self control P < 0.05 control # P < 0.01
4.5 improvement of the main symptoms:
TABLE 11 improvement of the chief symptoms
() Control group
4.6 detection of safety indexes:
4.6.1 comparison of maximum oxygen consumption Change with meal size
TABLE 12 maximum oxygen consumption before and after tasting (X + -SD)
The comparison between the maximum oxygen consumption per se before and after the test feeding and the group P is more than 0.05.
TABLE 13 comparison of dietary calories (kcal/day) before and after a test meal (X + -SD)
Dietary calories before and after the trial were > 0.05 by themselves and by comparison between groups.
4.6.2 general safety indices
Blood, urine, stool, heart rate, blood pressure, abdomen B-ultrasound, electrocardiogram and X-ray chest fluoroscopy, and the indexes are in normal range before and after the test.
5 conclusion
100 simple obese patients are randomly divided into a test group and a control group by a double-blind method, the test group takes the weight-reducing health-care food capsule, the control group is a blank control, after 5 weeks, the average weight of the test group is reduced by 2.53 +/-1.58 Kg, the weight of body fat is reduced by 1.40 +/-0.87 Kg, the percentage content of the body fat is reduced by 2.84 +/-1.78%, the difference between the body fat and the groups is obvious (P is less than 0.05), the waistline, abdominal wall and iliac spine sebum are reduced, the paired T test P before and after the test is less than 0.05, and the statistical difference is realized. Therefore, the weight-losing health-care food capsule prepared by the invention has obvious weight-losing effect.
Before and after the weight-losing health-care food capsule is eaten, clinical physical examination indexes such as hemoglobin, red blood cells, white blood cells, serum total protein, albumin, glutamic-oxaloacetic transaminase, glutamic-pyruvic transaminase, urea nitrogen, creatinine, blood uric acid, urine routine (including urine ketone bodies), stool routine and the like are basically in a normal range, and the weight-losing health-care food capsule has no adverse effect on the body health of a person who eats the weight-losing health-care food capsule.
After the weight-losing health-care food capsule is eaten, no allergy or other adverse reactions are caused.
Claims (7)
1. A health food with a weight-losing function is characterized by comprising the following raw materials in parts by weight: 3-15 parts of cassia seed extract, 3-15 parts of lotus leaf extract, 2-10 parts of tea polyphenol and 15-30 parts of L-carnitine;
the preparation method of the cassia seed extract comprises the following steps: weighing semen cassiae, crushing, performing reflux extraction for 2-3 times by adopting 50-75% edible alcohol, adding 4-6 times of edible alcohol by weight each time, extracting for 1-2 hours each time, and then filtering, concentrating, spray drying and packaging to obtain semen cassiae extract;
the preparation method of the lotus leaf extract comprises the following steps: weighing lotus leaves, crushing, adding 6-10 times of water by weight, performing reflux extraction for 3-4 times for 1-2 h each time, and then filtering, concentrating, spray drying and packaging to obtain a lotus leaf extract;
the water content of the cassia seed extract and the lotus leaf extract is less than or equal to 5 percent.
2. The health food with the weight-losing function as claimed in claim 1, which comprises the following raw materials in parts by weight: 4-10 parts of cassia seed extract, 4-10 parts of lotus leaf extract, 2-8 parts of tea polyphenol and 15-25 parts of L-carnitine.
3. The health food with weight-reducing function as claimed in claim 1, wherein the spray-dried has an inlet temperature of 180 ℃ to 200 ℃ and an outlet temperature of 80 ℃ to 90 ℃.
4. A method for preparing the health food with weight-reducing function as claimed in claim 1, comprising the steps of:
s1, weighing the cassia seed extract, the lotus leaf extract, the tea polyphenol and the L-carnitine according to the formula, sieving by a 40-60-mesh sieve, and placing in a mixer;
s2, weighing the auxiliary materials according to the formula, sieving the auxiliary materials by a 40-60-mesh sieve, placing the auxiliary materials in a mixer, and mixing the auxiliary materials with the raw materials obtained in the step S1 for 20-40 min to prepare a total mixed material;
s3, encapsulating, polishing and packaging the total mixed material obtained in the step S2 to obtain capsules.
5. The method for preparing a health food with weight-reducing function as claimed in claim 4, wherein the adjuvant in step S2 is magnesium stearate, and the added amount is 0.3-0.9 parts.
6. The method for preparing a health food with weight-reducing function as claimed in claim 4, wherein the food can be further prepared into tablet or pill after step S1.
7. The health food with weight-losing function according to any one of claims 1 to 3, which is suitable for the weight-losing effect of people with simple obesity.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010479158.7A CN111543635A (en) | 2020-05-29 | 2020-05-29 | Health food with weight reducing function and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010479158.7A CN111543635A (en) | 2020-05-29 | 2020-05-29 | Health food with weight reducing function and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111543635A true CN111543635A (en) | 2020-08-18 |
Family
ID=71997316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010479158.7A Pending CN111543635A (en) | 2020-05-29 | 2020-05-29 | Health food with weight reducing function and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111543635A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113854559A (en) * | 2021-09-23 | 2021-12-31 | 营养屋(成都)生物医药有限公司 | Weight-losing health food and preparation method thereof |
| CN114098088A (en) * | 2021-11-30 | 2022-03-01 | 哈尔滨怡康药业有限公司 | Health preserving composition suitable for regulating body fat of different people and preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101530208A (en) * | 2009-04-13 | 2009-09-16 | 杭州余杭区塘栖镇亿万水晶茶经营部 | Lotus leaf crystal tea |
| CN103284146A (en) * | 2013-05-16 | 2013-09-11 | 汤臣倍健股份有限公司 | L-carnitine tea polyphenol tablet and preparation method thereof |
| CN203436580U (en) * | 2013-06-03 | 2014-02-19 | 船井生医股份有限公司 | Smooth slimming capsule structure capable of preventing and treating obesity and promoting micro-lipid metabolism |
| CN103610054A (en) * | 2013-11-27 | 2014-03-05 | 营养屋(成都)生物医药有限公司 | Healthcare food with effects of reducing weight and facilitating feces excretion and preparation method thereof |
-
2020
- 2020-05-29 CN CN202010479158.7A patent/CN111543635A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101530208A (en) * | 2009-04-13 | 2009-09-16 | 杭州余杭区塘栖镇亿万水晶茶经营部 | Lotus leaf crystal tea |
| CN103284146A (en) * | 2013-05-16 | 2013-09-11 | 汤臣倍健股份有限公司 | L-carnitine tea polyphenol tablet and preparation method thereof |
| CN203436580U (en) * | 2013-06-03 | 2014-02-19 | 船井生医股份有限公司 | Smooth slimming capsule structure capable of preventing and treating obesity and promoting micro-lipid metabolism |
| CN103610054A (en) * | 2013-11-27 | 2014-03-05 | 营养屋(成都)生物医药有限公司 | Healthcare food with effects of reducing weight and facilitating feces excretion and preparation method thereof |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113854559A (en) * | 2021-09-23 | 2021-12-31 | 营养屋(成都)生物医药有限公司 | Weight-losing health food and preparation method thereof |
| CN114098088A (en) * | 2021-11-30 | 2022-03-01 | 哈尔滨怡康药业有限公司 | Health preserving composition suitable for regulating body fat of different people and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100506056C (en) | Slimming tea and preparation method thereof | |
| CN102187887B (en) | Sandwich biscuit with functions of losing weight and regulating blood sugar and production method thereof | |
| CN100420391C (en) | Health-care food with anti-oxidation and lowering weight functions | |
| WO2015172608A1 (en) | Capsule for assisting in reducing blood fat and preparation method therefor | |
| CN108095113A (en) | A kind of composition, preparation and its application with fat reducing blood sugar reducing function | |
| CN102940733A (en) | Composition for relieving physical fatigue and preparation method and application thereof | |
| CN111543635A (en) | Health food with weight reducing function and preparation method thereof | |
| CN109700011A (en) | A kind of health food and preparation method thereof improving sleep | |
| CN103284146A (en) | L-carnitine tea polyphenol tablet and preparation method thereof | |
| CN101356975B (en) | Health food capable of increasing human immunity and promoting intelligence and strengthening brain and preparation method thereof | |
| CN110742269B (en) | Memory enhancing composition suitable for postpartum women and preparation method thereof | |
| CN101356972A (en) | Anti-fatigue anti-hypoxia sports health food | |
| CN101904501B (en) | Functional food for relieving fatigue and preparation method thereof | |
| CN113854559A (en) | Weight-losing health food and preparation method thereof | |
| CN105920180A (en) | Health food with efficacy of relaxing bowel and preparation method of health food | |
| CN105995980B (en) | A kind of composition and preparation method thereof with Weight management effect | |
| CN108835313A (en) | Radix Salviae Miltiorrhizae lotus leaf is made light of one's life by commiting suicide tea and the preparation method and application thereof | |
| CN104740088A (en) | Weight reduction compound composition and preparation method thereof | |
| CN108095082A (en) | A kind of health food containing curcumin and preparation method thereof | |
| CN116077604B (en) | Traditional Chinese medicine composition for assisting in reducing blood sugar | |
| CN108904596A (en) | It is a kind of to have effects that improve the composition of memory | |
| CN102552643A (en) | Combination with blood fat reducing function and application of same | |
| CN107136518A (en) | Nutrient powder with effect of weight reducing and preparation method thereof | |
| CN101703128B (en) | Health protection tea and preparation process thereof | |
| CN108260815A (en) | It is a kind of have the function of reducing blood lipid, weight-reducing health food and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200818 |